{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "AUD", "exchange": "ASX", "shortName": "CLARITY PH FPO", "longName": "Clarity Pharmaceuticals Ltd", "messageBoardId": "finmb_263530964", "exchangeTimezoneName": "Australia/Sydney", "exchangeTimezoneShortName": "AEST", "gmtOffSetMilliseconds": 36000000, "market": "au_market", "esgPopulated": false, "regularMarketChangePercent": -4.0540586, "regularMarketPrice": 0.71, "marketState": "POSTPOST", "firstTradeDateMilliseconds": 1629849600000, "priceHint": 4, "epsTrailingTwelveMonths": -0.08, "epsForward": -0.11, "sharesOutstanding": 260379008, "bookValue": 0.315, "fiftyDayAverage": 0.78105, "fiftyDayAverageChange": -0.07105005, "fiftyDayAverageChangePercent": -0.09096734, "twoHundredDayAverage": 0.7846625, "twoHundredDayAverageChange": -0.07466251, "twoHundredDayAverageChangePercent": -0.095152386, "marketCap": 184869088, "forwardPE": -6.4545455, "priceToBook": 2.2539682, "sourceInterval": 20, "exchangeDataDelayedBy": 20, "averageAnalystRating": "1.7 - Buy", "tradeable": false, "cryptoTradeable": false, "regularMarketChange": -0.030000031, "regularMarketTime": 1683871827, "regularMarketDayHigh": 0.73, "regularMarketDayRange": "0.71 - 0.73", "regularMarketDayLow": 0.71, "regularMarketVolume": 73425, "regularMarketPreviousClose": 0.74, "bid": 0.71, "ask": 0.725, "fullExchangeName": "ASX", "financialCurrency": "AUD", "regularMarketOpen": 0.73, "averageDailyVolume3Month": 165429, "averageDailyVolume10Day": 58441, "fiftyTwoWeekLowChange": 0.34999996, "fiftyTwoWeekLowChangePercent": 0.9722221, "fiftyTwoWeekRange": "0.36 - 1.05", "fiftyTwoWeekHighChange": -0.33999997, "fiftyTwoWeekHighChangePercent": -0.3238095, "fiftyTwoWeekLow": 0.36, "fiftyTwoWeekHigh": 1.05, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "symbol": "CU6.AX"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "National Innovation Centre", "address2": "4 Cornwallis Street Eveleigh", "city": "Sydney", "state": "NSW", "zip": "2015", "country": "Australia", "phone": "61 2 9209 4037", "fax": "61 2 9209 4037", "website": "https://www.claritypharmaceuticals.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Alan John Taylor Ph.D.", "title": "Exec. Chairman", "fiscalYear": 2022, "totalPay": {"raw": 690844, "fmt": "690.84k", "longFmt": "690,844"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Colin David Biggin Ph.D.", "title": "MD, CEO & Exec. Director", "fiscalYear": 2022, "totalPay": {"raw": 492474, "fmt": "492.47k", "longFmt": "492,474"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. David K. Green BEc., CA", "title": "Chief Financial Officer", "fiscalYear": 2022, "totalPay": {"raw": 110406, "fmt": "110.41k", "longFmt": "110,406"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Robert  Vickery", "title": "Company Sec.", "fiscalYear": 2022, "totalPay": {"raw": 163099, "fmt": "163.1k", "longFmt": "163,099"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Michael D. Ironside", "title": "Director of Operations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Jeffrey  Norenberg", "title": "Chief Scientific Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Ellen  van Dam Ph.D.", "title": "Head of R&D", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Shaemus  Gleason", "title": "Exec. VP of US Operations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Robert M. Miller Ph.D.", "age": 70, "title": "Consultant Chief Medical Officer", "yearBorn": 1952, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. William  Cheadle", "title": "Financial Controller", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}